NEW PERSPECTIVES IN THE TREATMENT OF ULCERATIVE COLITIS IN ADULTS - IL-23 INHIBITORS: EFFICACY AND SAFETY
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6077Keywords:
Ulcerative Colitis, Inflammatory Bowel Disease, IL-23 Inhibitors, Mirikizumab, Risankizumab, Guselkumab, ReviewAbstract
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation of the colon resulting from immune dysregulation. Despite the availability of multiple therapeutic options, a substantial proportion of patients fail to achieve sustained remission or develop loss of response to existing therapies. Increasing evidence has identified the interleukin-23 (IL-23)/Th17 pathway as a key mechanism involved in the pathogenesis of UC, leading to the development of selective IL-23 inhibitors as novel therapeutic agents.
Purpose: The aim of this study was to review and summarize current evidence regarding the efficacy and safety of IL-23 inhibitors, particularly mirikizumab, risankizumab and guselkumab, in the treatment of moderate-to-severe ulcerative colitis.
Methodology: A narrative literature review was performed using PubMed and ClinicalTrials.gov to identify relevant studies investigating IL-23 inhibitors in the treatment of ulcerative colitis. The review included phase II and phase III randomized controlled trials, long term extension studies, real-world observational cohorts, systematic reviews and meta-analyses. Data were extracted and synthesized to provide a comprehensive assessment of the efficacy, safety and evolving therapeutic role of IL-23 inhibitors in ulcerative colitis.
Conclusions: Available evidence indicates that IL-23 inhibitors are effective therapeutic options for patients with moderate-to-severe ulcerative colitis. Mirikizumab, risankizumab and guselkumab demonstrated significant improvements in clinical remission, endoscopic healing, histologic outcomes and quality of life. Among these agents, mirikizumab currently has the strongest evidence supporting long-term efficacy and durability of response. IL-23 inhibitors also demonstrated favorable safety profiles, with low rates of serious adverse events and treatment discontinuation. Although further real-world data and head-to-head comparative studies are still needed, selective IL-23 blockade represents a promising advancement in personalized UC treatment strategies.
References
Abraham, B., Wu, J., Vermeire, S., Melmed, G., Ungaro, R., Charabaty, A., Moses, R., Chan-Diehl, F., Paulissen, J., Zhu, B., Barnes, E. L., Ehrlich, A. C., & Rubin, D. T. (2025). Efficacy and safety of mirikizumab in the treatment of moderately to severely active ulcerative colitis regardless of baseline modified Mayo score: Results from the phase 3 LUCENT trials. Crohn’s & Colitis 360, 7(2), otaf002. https://doi.org/10.1093/crocol/otaf002
Abraham, C., & Cho, J. (2009). Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflammatory Bowel Diseases, 15(7), 1090–1100. https://doi.org/10.1002/ibd.20894
Ananthakrishnan, A. N., Murad, M. H., Scott, F. I., Agrawal, M., Haydek, J. P., Limketkai, B. N., Loftus, E. V., & Singh, S. (2024). Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American gastroenterological association evidence synthesis. Gastroenterology, 167(7), 1460–1482. https://doi.org/10.1053/j.gastro.2024.07.046
Chen, B., Ye, B. D., Cao, Q., Hirai, F., Saruta, M., Chen, M., Pelak, S., Shipitofsky, N., Miao, Y., Herr, K., Wahking, B., Zhuo, J., & Hisamatsu, T. (2025). Guselkumab in East Asians with moderate-to-severe ulcerative colitis: Subgroup analysis of the QUASAR induction and maintenance studies. Journal of Gastroenterology and Hepatology, 40(9), 2197–2208. https://doi.org/10.1111/jgh.17036
Chen, X., Si, G., Li, Y., & Yuan, X. (2025). Efficacy and safety of mirikizumab in the treatment of inflammatory bowel disease: A meta-analysis. Medicine, 104(17), e42123. https://doi.org/10.1097/MD.0000000000042123
Chu, X., Biao, Y., Liu, C., Zhang, Y., Liu, C., Ma, J.-Z., Guo, Y., & Gu, Y. (2023). Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. BMC Gastroenterology, 23(1), 346. https://doi.org/10.1186/s12876-023-02938-6
Chua, L., Friedrich, S., & Zhang, X. C. (2023). Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: Results from phase III LUCENT studies. Clinical Pharmacokinetics, 62(10), 1479–1491. https://doi.org/10.1007/s40262-023-01281-z
Colombel, J.-F., Wu, J., Kobayashi, T., Zhu, B., Paulissen, J., Dhanabal, A., Jairath, V., Siegel, C., Siegmund, B., Redondo, I., Moses, R., & Magro, F. (2025). Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: Analysis of a pre-specified LUCENT trial endpoint. Journal of Crohn’s & Colitis, 19(9), jjaf124. https://doi.org/10.1093/ecco-jcc/jjaf124
Dai, Y., Yang, W., Xu, L., Pan, P., Liu, S., Sun, Y., Hu, S., Li, Q., & Hu, F. (2025). Comparative efficacy of different targeted therapies in patients with moderate-to-severe ulcerative colitis: Systematic review/network meta-analysis and mechanistic overview. Pharmacology Research & Perspectives, 13(3), e70108. https://doi.org/10.1002/prp2.70108
D’Amico, F., Magro, F., Dignass, A., Al Awadhi, S., Gutierrez Casbas, A., Queiroz, N. S. F., Rydzewska, G., Duk Ye, B., Ran, Z., Hart, A., Jairath, V., Fiorino, G., Peyrin-Biroulet, L., & Danese, S. (2024). Practical management of mild-to-moderate ulcerative colitis: An international expert consensus. Expert Review of Gastroenterology & Hepatology, 18(8), 421–430. https://doi.org/10.1080/17474124.2024.2397650
Danese, S., Vermeire, S., Zhou, W., Pangan, A. L., Siffledeen, J., Greenbloom, S., Hébuterne, X., D’Haens, G., Nakase, H., Panés, J., Higgins, P. D. R., Juillerat, P., Lindsay, J. O., Loftus, E. V., Sandborn, W. J., Reinisch, W., Chen, M.-H., Sanchez Gonzalez, Y., Huang, B., … Panaccione, R. (2022). Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet, 399(10341), 2113–2128. https://doi.org/10.1016/S0140-6736(22)00581-5
Dubinsky, M. C., Jairath, V., Feagan, B. G., Naegeli, A. N., Tuttle, J., Morris, N., Shan, M., Arora, V., Lissoos, T., Agada, N., Hibi, T., & Sands, B. E. (2023). Changes in health-related quality of life and associations with improvements in clinical efficacy: A phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterology, 10(1), e001115. https://doi.org/10.1136/bmjgast-2023-001115
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Assche, G. V., Axler, J., Kim, H.-J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., & Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 369(8), 699–710. https://doi.org/10.1056/NEJMoa1215734
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., de Sousa, H. T., Dignass, A., Carbonnel, F., & for the European Crohn’s and Colitis Organisation [ECCO]. (2017). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current Management. Journal of Crohn’s and Colitis, 11(7), 769–784. https://doi.org/10.1093/ecco-jcc/jjx009
Hart, A., Sridhar, S., Venkat, S., Lee, T., Rusbuldt, J. J., Richards, D., Sisk, C., Horowitz, D., Tomsho, L., Kannan, A. K., Ruane, D., Van den Berge, K., Rubin, D. T., Sands, B. E., De Hertogh, G., Huang, K.-H. G., Germinaro, M., Cua, D., Waterworth, D., … Branigan, P. (2026). Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis. BMJ Open Gastroenterology, 13(1), e002153. https://doi.org/10.1136/bmjgast-2025-002153
Huang, L., Kong, C., Yue, N., Zhao, H., Zhang, Y., Tian, C., Mai, Z., Wei, D., Shi, R., Yao, J., Wang, L., & Li, D. (2025). What is the optimal biological therapy for moderate to severe ulcerative colitis: A systematic review and network meta-analysis. Frontiers in Pharmacology, 16, 1602024. https://doi.org/10.3389/fphar.2025.1602024
Johnson, T., Steere, B., Zhang, P., Zang, Y., Higgs, R., Milch, C., Reinisch, W., Panés, J., Huang, K., D’Haens, G., & Krishnan, V. (2023). Mirikizumab-induced transcriptome changes in ulcerative colitis patient biopsies at week 12 are maintained through week 52. Clinical and Translational Gastroenterology, 14(11), e00630. https://doi.org/10.14309/ctg.0000000000000630
Khan, S. A., Marasini, A., Khanam, B., Shrestha, A., Khan, S., Kausar, H., Kauser, H., Parajuli, S. B., & Khan, E. (2026). Efficacy of mirikizumab induction therapy in inflammatory bowel disease: A systematic review and meta-analysis. Medicine, 105(5), e47508. https://doi.org/10.1097/MD.0000000000047508
Levartovsky, A., Lukáš, M., Abitbol, C. M., Vlková, K., Ben-Horin, S., Lukáš, M., & Kopylov, U. (2025). Mirikizumab in ulcerative colitis: Real-world evidence from an international two-center retrospective cohort study. Therapeutic Advances in Gastroenterology, 18, 17562848251392074. https://doi.org/10.1177/17562848251392074
Louis, E., Schreiber, S., Panaccione, R., Bossuyt, P., Biedermann, L., Colombel, J.-F., Parkes, G., Peyrin-Biroulet, L., D’Haens, G., Hisamatsu, T., Siegmund, B., Wu, K., Boland, B. S., Melmed, G. Y., Armuzzi, A., Levine, P., Kalabic, J., Chen, S., Cheng, L., … INSPIRE and COMMAND Study Group. (2024a). Risankizumab for ulcerative colitis: Two randomized clinical trials. JAMA, 332(11), 881–897. https://doi.org/10.1001/jama.2024.12414
Louis, E., Schreiber, S., Panaccione, R., Bossuyt, P., Biedermann, L., Colombel, J.-F., Parkes, G., Peyrin-Biroulet, L., D’Haens, G., Hisamatsu, T., Siegmund, B., Wu, K., Boland, B. S., Melmed, G. Y., Armuzzi, A., Levine, P., Kalabic, J., Chen, S., Cheng, L., … INSPIRE and COMMAND Study Group. (2024b). Risankizumab for ulcerative colitis: Two randomized clinical trials. JAMA, 332(11), 881–897. https://doi.org/10.1001/jama.2024.12414
Magro, F., Pai, R. K., Kobayashi, T., Jairath, V., Rieder, F., Redondo, I., Lissoos, T., Morris, N., Shan, M., Park, M., & Peyrin-Biroulet, L. (2023). Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes. Journal of Crohn’s & Colitis, 17(9), 1457–1470. https://doi.org/10.1093/ecco-jcc/jjad050
Marsal, J., Barreiro-de Acosta, M., Blumenstein, I., Cappello, M., Bazin, T., & Sebastian, S. (2022). Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Frontiers in Medicine, 9, 897936. https://doi.org/10.3389/fmed.2022.897936
Panaccione, R., Louis, E., Colombel, J.-F., D’Haens, G., Peyrin-Biroulet, L., Dubinsky, M., Takeuchi, K., Rubin, D. T., Kalabic, J., Chien, K. B., Chen, S., Cheng, L., Zhang, Y., Duan, W. R., Vladea, R., Hecht, P. M., Morisset, P., Schreiber, S., & Ferrante, M. (2025). Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: Post hoc analysis of the INSPIRE and COMMAND phase 3 studies. Journal of Crohn’s & Colitis, 19(1), jjaf005. https://doi.org/10.1093/ecco-jcc/jjaf005
Paridaens, K., Freddi, M. J., & Travis, S. P. L. (2024). The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis. Frontiers in Gastroenterology, 3. https://doi.org/10.3389/fgstr.2024.1335380
Parisio, L., Cuccia, G., Giudice, A., Carrabetta, F., Del Gaudio, A., Privitera, G., Carbone, L., Spagnuolo, R., & Pugliese, D. (2025). Interleukin 23: Pathogenetic involvement and therapeutic target for ulcerative colitis. Journal of Clinical Medicine, 14(13), 4590. https://doi.org/10.3390/jcm14134590
Peyrin-Biroulet, L., Allegretti, J. R., Rubin, D. T., Bressler, B., Germinaro, M., Huang, K.-H. G., Shipitofsky, N., Zhang, H., Wilson, R., Han, C., Feagan, B. G., Sandborn, W. J., Panés, J., Hisamatsu, T., Lichtenstein, G. R., Sands, B. E., Dignass, A., & QUASAR Study Group. (2023). Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology, 165(6), 1443–1457. https://doi.org/10.1053/j.gastro.2023.08.038
Ran, Z., Chen, Y., Miao, Y., Wang, Y., Gao, X., Zhong, J., Ding, X., Wang, C., Zhang, X., Ding, Y., Hu, N., Tang, D., Yu, J., Qian, C., & Shen, J. (2026). Mirikizumab as induction and maintenance therapy in Chinese patients with ulcerative colitis: A subpopulation analysis of the randomized, global phase 3 LUCENT-1 and LUCENT-2 trials. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. https://doi.org/10.1007/s40259-026-00776-y
Reinisch, W., Loftus, E. V., Schreiber, S., Rubin, D. T., Louis, E., Hecht, P. M., Barrachina, E. M., Kalabic, J., Vladea, R., Sharma, D., Duan, W. R., Zhang, Y., & Panaccione, R. (2025). Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. Journal of Crohn’s & Colitis, 19(4), jjaf025. https://doi.org/10.1093/ecco-jcc/jjaf025
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG clinical guideline: Ulcerative colitis in adults. Official Journal of the American College of Gastroenterology | ACG, 114(3), 384. https://doi.org/10.14309/ajg.0000000000000152
Sandborn, W. J., Feagan, B. G., D’Haens, G., Wolf, D. C., Jovanovic, I., Hanauer, S. B., Ghosh, S., Petersen, A., Hua, S. Y., Lee, J. H., Charles, L., Chitkara, D., Usiskin, K., Colombel, J.-F., Laine, L., & Danese, S. (2021). Ozanimod as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 385(14), 1280–1291. https://doi.org/10.1056/NEJMoa2033617
Sandborn, W. J., Ferrante, M., Bhandari, B. R., Berliba, E., Hibi, T., D’Haens, G. R., Tuttle, J. L., Krueger, K., Friedrich, S., Durante, M., Arora, V., Naegeli, A. N., Schmitz, J., & Feagan, B. G. (2022). Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 20(1), 105-115.e14. https://doi.org/10.1016/j.cgh.2020.09.028
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., Friedman, G., Lawendy, N., Yu, D., Woodworth, D., Mukherjee, A., Zhang, H., Healey, P., Panés, J., & OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. (2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine, 376(18), 1723–1736. https://doi.org/10.1056/NEJMoa1606910
Sands, B. E., D’Haens, G., Clemow, D. B., Irving, P. M., Johns, J. T., Gibble, T. H., Abreu, M. T., Lee, S. D., Hisamatsu, T., Kobayashi, T., Dubinsky, M. C., Vermeire, S., Siegel, C. A., Peyrin-Biroulet, L., Moses, R. E., Milata, J., Panaccione, R., & Dignass, A. (2025). Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: Results from the LUCENT-3 open-label extension study. Inflammatory Bowel Diseases, 31(7), 1876–1890. https://doi.org/10.1093/ibd/izae253
Sands, B. E., D’Haens, G., Clemow, D. B., Irving, P. M., Johns, J. T., Hunter Gibble, T., Abreu, M. T., Lee, S., Hisamatsu, T., Kobayashi, T., Dubinsky, M. C., Vermeire, S., Siegel, C. A., Peyrin-Biroulet, L., Moses, R. E., Milata, J., Arora, V., Panaccione, R., & Dignass, A. (2024). Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: Results from the LUCENT-3 open-label extension study. Inflammatory Bowel Diseases, 30(12), 2245–2258. https://doi.org/10.1093/ibd/izae024
Sands, B. E., Feagan, B. G., Hunter Gibble, T., Traxler, K. A., Morris, N., Eastman, W. J., Schreiber, S., Jairath, V., Long, M. D., & Armuzzi, A. (2023). Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: Results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies. Crohn’s & Colitis 360, 5(4), otad070. https://doi.org/10.1093/crocol/otad070
Sands, B. E., Sandborn, W. J., Panaccione, R., O’Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Marano, C., & UNIFI Study Group. (2019). Ustekinumab as induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine, 381(13), 1201–1214. https://doi.org/10.1056/NEJMoa1900750
Sawaf, B., Hayek, M. A., Kassem, A., Alsoud, D., Alom, M., Salam, A. H., Shembesh, R. H., Beshr, M. S., Hallak, Y., Abbarh, S., Batikh, E., Shibani, M., Elhadi, M., Alastal, Y., & Regueiro, M. (2025). Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Annals of Gastroenterology, 38(6), 648–660. https://doi.org/10.20524/aog.2025.1009
Steere, B., Beidler, C., Martin, A., Bright, S., Kikly, K., & Benschop, R. J. (2023). Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. The Journal of Pharmacology and Experimental Therapeutics, 387(2), 180–187. https://doi.org/10.1124/jpet.122.001512
Takagi, Y., Sato, T., Nishiguchi, T., Nogami, A., Igeta, M., Yagi, S., Ikenouchi, M., Kawai, M., Kamikozuru, K., Yokoyama, Y., Tomita, T., Fukui, H., Fukata, M., Kobayashi, T., & Shinzaki, S. (2025). Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: A multicentre retrospective observational study. Alimentary Pharmacology & Therapeutics, 61(12), 1923–1934. https://doi.org/10.1111/apt.70140
Torres, J., Panés, J., Siegel, C. A., Dubinsky, M. C., Dulai, P. S., Tanida, S., Danese, S., Kalabic, J., Lai, J.-H., Shukla, N., Rizzo, L., Holweg, C., Sharma, D., & Panaccione, R. (2025). Symptom resolution and meaningful improvement in quality of life with risankizumab in patients with ulcerative colitis: Post hoc analysis of the randomized INSPIRE and COMMAND studies. The American Journal of Gastroenterology, 120(8), 1820–1828. https://doi.org/10.14309/ajg.0000000000003420
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., Schölmerich, J., Bemelman, W., Danese, S., Mary, J. Y., Rubin, D., Colombel, J.-F., Peyrin-Biroulet, L., Dotan, I., Abreu, M. T., & Dignass, A. (2021). STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, 160(5), 1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031
Ungaro, R., Colombel, J.-F., Lissoos, T., & Peyrin-Biroulet, L. (2019). A treat-to-target update in ulcerative colitis: A systematic review. The American Journal of Gastroenterology, 114(6), 874–883. https://doi.org/10.14309/ajg.0000000000000183
Verstockt, B., Salas, A., Sands, B. E., Abraham, C., Leibovitzh, H., Neurath, M. F., Vande Casteele, N., & Alimentiv Translational Research Consortium (ATRC). (2023). IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nature Reviews. Gastroenterology & Hepatology, 20(7), 433–446. https://doi.org/10.1038/s41575-023-00768-1
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zuzanna Ostrowska, Zuzanna Witkowska, Bartosz Rutka, Barbara Maria Jastrzębska, Alicja Danieluk, Agnieszka Kulińska, Jakub Kądziela, Gabriela Soćko, Julia Tańska, Oskar Paprocki, Alicja Komorowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
